Genenta Science S.p.A. (NASDAQ:GNTA – Get Free Report) saw a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 5,000 shares, an increase of 47.1% from the May 31st total of 3,400 shares. Based on an average daily volume of 4,300 shares, the short-interest ratio is presently 1.2 days.
Genenta Science Trading Up 0.6 %
Shares of NASDAQ GNTA traded up $0.02 during mid-day trading on Monday, hitting $3.12. 4,424 shares of the stock traded hands, compared to its average volume of 4,682. Genenta Science has a twelve month low of $2.20 and a twelve month high of $6.39. The firm has a 50 day simple moving average of $3.25 and a two-hundred day simple moving average of $3.82.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Genenta Science in a research note on Monday, May 13th.
About Genenta Science
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Recommended Stories
- Five stocks we like better than Genenta Science
- What is an Earnings Surprise?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Profitably Trade Stocks at 52-Week Highs
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Capture the Benefits of Dividend Increases
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.
